- Conditions
- Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic
- Interventions
- upifitamab rilsodotin
- Drug
- Lead sponsor
- Mersana Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 523 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Platinum-sensitive Ovarian Cancer (UPGRADE-A)
- Interventions
- XMT-1536 (Upifitamab Rilsodotin), Carboplatin
- Drug
- Lead sponsor
- Mersana Therapeutics
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Grand Rapids, Michigan
- Conditions
- Platinum Resistant Ovarian Cancer, Non-Small Cell Adenocarcinoma
- Interventions
- upifitamab rilsodotin
- Drug
- Lead sponsor
- Mersana Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Interventions
- Upifitimab rilsodotin, Placebo
- Drug · Other
- Lead sponsor
- Mersana Therapeutics
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 23 more
- Conditions
- Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic
- Interventions
- upifitamab rilsodotin
- Drug
- Lead sponsor
- Mersana Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma